Compare KKR & Co Inc (KKR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Regeneron Pharmaceuticals Inc — how do they compare? KKR & Co Inc trades at $111.68 (market cap $99.61B), while Regeneron Pharmaceuticals Inc trades at $796.8 (market cap $82.06B). The key difference: KKR & Co Inc is the larger of the two by market cap, and KKR & Co Inc pays the higher dividend (0.7%). Which is the better fit depends on your goals.
| KKR | REGN | |
|---|---|---|
Market Cap | $99.61B | $82.06B |
Sector | Financials | Health |
52-Week High | $149.34 | $812.27 |
52-Week Low | $83.88 | $555.51 |
Enterprise Value | $22.17B | $76.77B |
Dividend Yield | 0.7% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $103.83, up 0.99% with strong bullish momentum. The stock shows robust earnings performance with Q2 2026 EPS of $1.63 beating estimates of $1.43, continuing a trend of positive surprises. Recent acquisitions including Integer Holdings ($4.3B) and Medicover India ($1.39B) demonstrate aggressive growth strategy. Analyst consensus remains overwhelmingly bullish with 24 buy ratings and $127.22 price target, representing 22.5% upside potential from current levels.
KKR presents compelling investment opportunity with strong fundamentals, consistent earnings beats, and strategic acquisitions driving growth. Key risks include integration challenges from recent deals, market volatility affecting asset management fees, and potential regulatory scrutiny of private equity operations. The company's $19.2B infrastructure fund closure signals strong institutional confidence in long-term strategy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
